EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phage-Mediated Amikacin Dose Sparing Against Pseudomonas aeruginosa and Klebsiella aerogenes: In Vitro Synergy and In Vivo Validation

Anandakrishnan Gopalakrishnan Nair, Rahul Ani, Veena Muralikumar Nair, Niti Sarat, Bipin Gopalakrishnan Nair, Sanjay Pal, Suja Subhash

Antibiotics · 09.11.2026 · 15 (11) · 1113

DOI: 10.3390/antibiotics15111113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibiotics, online erschienen am 09.11.2026. Verfasst von Anandakrishnan Gopalakrishnan Nair und 6 weiteren Autor:innen. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: School of Biotechnology, Amrita Vishwa Vidyapeetham.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Phage–antibiotic synergy (PAS) offers a potential strategy to enhance antibacterial activity. This study evaluated phage–amikacin interactions against Pseudomonas aeruginosa and Klebsiella aerogenes using in vitro assays and a Caenorhabditis elegans infection model.

Methods

Two lytic bacteriophages ɸPh_Pae_AS2 and ɸPh_Eae_AS3 were characterized for morphology, host range, lytic activity, and environmental stability. Phage–amikacin interactions were assessed using checkerboard and time-kill assays, bacterial viable counts, phage-titre measurements, and biofilm assays. In vivo efficacy was evaluated using C. elegans.

Results

Both phages exhibited lytic activity and environmental stability. Checkerboard assays demonstrated synergistic interaction yielding fractional inhibitory concentration indices (FICIs) of 0.072 and 0.041 against P. aeruginosa and K. aerogenes, respectively. Under the tested conditions, phage addition reduced the amikacin concentration required to achieve ≥90% growth inhibition by approximately 16-fold and 32-fold, respectively. Antibiofilm efficacy was species- and maturity-dependent. Combination treatment enhanced biofilm inhibition in both species and disruption of mature K. aerogenes biofilms but provided no clear additional benefit over monotherapy against mature P. aeruginosa biofilms. In the C. elegans model, combination treatment improved survival, although the magnitude of improvement over monotherapy varied between the two systems.

Conclusions

Phage–amikacin combinations demonstrated substantial in vitro synergy against P. aeruginosa and K. aerogenes, markedly reducing the amikacin concentrations required for growth inhibition under the tested conditions. These findings highlight the potential of phage–antibiotic combinations as an antibiotic-sparing strategy, although the in vitro reductions do not establish clinical dose-sparing benefits. Further validation using diverse clinical isolates and mammalian infection models is warranted to determine their translational potential.

Förderung

  • School of Biotechnology, Amrita Vishwa Vidyapeetham

Zitieren

APA

Nair, A. G., Ani, R., Nair, V. M., Sarat, N., Nair, B. G., Pal, S., & Subhash, S. (2026). Phage-Mediated Amikacin Dose Sparing Against Pseudomonas aeruginosa and Klebsiella aerogenes: In Vitro Synergy and In Vivo Validation. Antibiotics, 15(11), 1113. https://doi.org/10.3390/antibiotics15111113

Vancouver

Nair AG, Ani R, Nair VM, Sarat N, Nair BG, Pal S, et al. Phage-Mediated Amikacin Dose Sparing Against Pseudomonas aeruginosa and Klebsiella aerogenes: In Vitro Synergy and In Vivo Validation. Antibiotics. 2026;15(11):1113. doi:10.3390/antibiotics15111113

BibTeX
@article{Nair2026,
  author = {Nair, Anandakrishnan Gopalakrishnan and Ani, Rahul and Nair, Veena Muralikumar and Sarat, Niti and Nair, Bipin Gopalakrishnan and Pal, Sanjay and Subhash, Suja},
  title = {Phage-Mediated Amikacin Dose Sparing Against Pseudomonas aeruginosa and Klebsiella aerogenes: In Vitro Synergy and In Vivo Validation},
  journal = {Antibiotics},
  year = {2026},
  volume = {15},
  number = {11},
  pages = {1113},
  doi = {10.3390/antibiotics15111113}
}
Kostenlos starten →